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Introduction
Proton-pump inhibitors (PPIs) are commonly used 
in clinical practice for gastric-acid suppression, par-
ticularly for the prevention of stress ulcers in criti-
cally ill patients. However, an increased risk of some 
negative clinical outcomes has been reported, 
including kidney disease, hypomagnesemia, bone 
fractures, pneumonia, and Clostridium difficile infec-
tions (CDIs).1,2 A recent study raised alarm by sug-
gesting that initiating PPIs during hospital admission 
could increase the risk of inpatient mortality by 
about 90%.3 While older data have suggested that 
acid suppression allows for increased intestinal bac-
teria, some analyses found this overgrowth occurred 
less with histamine antagonists, conceivably related 
to less potent gastric-acid suppression from hista-
mine antagonists when compared with PPIs.4 
Moreover, PPIs have been associated with decreased 
leukocyte antimicrobial activity in vitro, as well as 
attenuated innate immune responses in vivo that 
may be beneficial in clearance of bacterial infection.5 
We thought it would be important to examine if 
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Abstract
Background: Proton-pump inhibitors (PPIs) are commonly used in clinical practice for 
gastric acid suppression. However, these agents have also been associated with certain 
negative clinical outcomes. We evaluated the real-world effects of incident PPI use on clinical 
outcomes in patients with Staphylococcus aureus bacteremia.
Methods: This retrospective cohort study included patients admitted to Veterans Affairs 
hospitals with positive S. aureus blood cultures collected between 2002 and 2013 that received 
appropriate antibiotics within 48 hours of culture collection. Clinical outcomes among three 
PPI exposure groups, each compared to nonusers, were assessed with propensity-score-
matched Cox proportional-hazard regression models: pretreated PPI users initiating therapy 
in the 30 days prior to culture and either (a) continuing PPI therapy after culture, or (b) not 
continuing after culture, and (c) de novo users initiating at culture.
Results: Clinical outcomes, including inpatient mortality, intensive care discharge, 30-
day mortality, 30-day readmission, and 30-day Clostridium difficile infection (CDI) were 
similar among PPI users and nonusers. Though length of stay was longer in pretreated, 
continuing PPI users [time-to-discharge hazard ratio (HR) 0.78, 95% confidence interval 
(CI) 0.65–0.93], 14-day mortality was significantly lower than in nonusers (HR 0.66, 95% CI 
0.50–0.87).
Conclusions: In our large national cohort study, PPIs were not associated with an increased 
risk of negative clinical outcomes, including mortality and CDI, in patients with S. aureus 
bacteremia.
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these reported immunomodulatory effects described 
for PPIs translated into any clinical outcome differ-
ences in patients with invasive infection. Among the 
most common of invasive bacterial infection in 
humans, Staphylococcus aureus affects broad patient 
populations exhibiting high diversity in baseline host 
innate immune status. This study sought to evaluate 
the real-world effects of incident PPI use on clinical 
outcomes in patients with S. aureus bacteremia.
Methods
Data source
We utilized national Veterans Affairs (VA) data-
bases, which contain health and administrative 
data captured from electronic medical records. 
The databases used included diagnoses and proce-
dures from outpatient and inpatient care, labora-
tory and microbiology results, vital signs and vital 
status, and pharmacy data, including inpatient and 
outpatient administration and dispensing, and 
medications prescribed by non-VA providers or 
purchased by patients at non-VA pharmacies.
Study population
This retrospective cohort study included adult 
patients (age ⩾ 18 years) admitted to VA hospitals 
with positive blood cultures for S. aureus between 
1 January 2002 and 1 December 2013. Initial anti-
biotic regimens within 48 hours of culture collec-
tion were reviewed and only those with appropriate 
regimens were selected for inclusion: intravenous 
β-lactam therapy (ampicillin-sulbactam, nafcillin, 
oxacillin, piperacillin–tazobactam, cefazolin, cefo-
tetan, cefoxitin, ceftazidime, ceftriaxone, ceftaro-
line, ertapenem, doripenem, imipenem–cilastatin, 
or meropenem) or vancomycin for methicillin-sus-
ceptible S. aureus (MSSA) and vancomycin or cef-
taroline for methicillin-resistant S. aureus (MRSA). 
If patients were discharged within 1 day of culture 
or died in that same timeframe, they were excluded. 
Once these criteria were applied, the first admis-
sion was selected for analysis.
This study was approved by the Institutional 
Review Board and Research and Development 
Committee of the Providence Veterans Affairs 
Medical Center. 
As this study utilized existing health data, a waiver 
of informed consent was granted by the 
Institutional Review Board of the Providence 
Veterans Affairs Medical Center.
PPI use
Incident PPI use was defined as initiation of a PPI 
within the 30 days prior to culture or at culture, 
without PPI use in the previous year. Those initi-
ating prior to culture were further categorized as 
continuing after culture and not continuing after 
culture, to assess whether lasting effects were 
observed after discontinuation. Nonusers were 
those with no record of PPI use in the year prior to 
culture or during the entire admission and served 
as the comparison group for all three PPI user 
groups (pretreated with continuation, pretreated 
without continuation, and de novo at culture).
Outcomes
The primary outcome was mortality as assessed 
within 30 days of the culture collection date 
and the secondary outcomes included 14-day 
mortality, inpatient mortality, hospital discharge, 
intensive care unit (ICU) discharge, 30-day 
readmission, and 30-day CDI (International 
Classification of Diseases, 9th edition, 008.45). 
We calculated time for each endpoint from the 
culture collection date to the event date, and cen-
soring was used in the assessments of discharge, 
readmission, and CDI for patients who died.
Statistical analysis
We developed three separate propensity-score models 
for each PPI exposure group that controlled for initial 
antibiotic treatment, treating facility, treating spe-
cialty, infection source, previous healthcare expo-
sures, demographics, current comorbidities, medical 
history, and other clinical characteristics, such as MSSA/
MRSA (Appendix 1 in the Supplementary Material). 
We confirmed goodness of fit and absence of multi-
collinearity in the propensity-score models. Nonusers 
were then matched to users on their propensity score 
using nearest neighbor matching within 0.005 caliper. 
Lastly, Cox proportional hazard regression models 
were used to quantify the hazard ratio (HR) and 95% 
confidence interval (CI) for all outcomes. Analyses 
were performed using SAS software version 9.2 (SAS 
Institute Inc., Cary, NC, USA).
Results
Our study included 653 pretreated PPI users 
without continuation, 642 pretreated PPI users 
with continuation, 900 de novo PPI users, and 
11,840 nonusers, all with S. aureus bacteremia 
(Figure 1). Table 1 lists demographics and clini-
cal characteristics of patients in each of these 
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groups prior to implementation of propensity-
score matching. PPI users differed considerably 
from nonusers, in terms of demographic charac-
teristics, source of infection, comorbidity bur-
den, and medical history. Due to these significant 
differences, these variables were included in the 
propensity-score models. Each model demon-
strated goodness of fit, allowing strong discrimi-
nation between the groups, with high C statistics 
of 0.82–0.90, and due to the small caliper used 
for identifying matches, complete overlap in 
propensity-score distributions between PPI users 
and nonusers was obtained.
In propensity-matched analyses of the aforemen-
tioned clinical outcomes, there were few differences 
observed between PPI users and nonusers (Table 
2). Inpatient mortality, intensive care discharge, 
30-day mortality, 30-day readmission, and 30-day 
CDI were similar among PPI users and nonusers. 
In pretreated PPI users with continuation, the 
14-day mortality rate was significantly lower (HR 
0.66, 95% CI 0.50–0.87) despite a lower discharge 
rate (HR 0.78, 0.65–0.92). This lower discharge 
rate, which reflected a longer length of stay, was 
also observed in de novo PPI users (HR 0.85, 95% 
CI 0.74–0.97) as compared with nonusers. Similar 
results were observed in sensitivity analyses that 
excluded patients with a C. difficile diagnosis code 
during the S. aureus bacteremia admission, where 
14-day mortality was significantly lower (HR 0.62, 
95% CI 0.42–0.92) among pretreated PPI users 
Figure 1. Study cohort identification.
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PPI, proton-pump 
inhibitor.
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De novo  
(n = 900)
Age (years) 68.8 ± 11.8 68.8 ± 11.6 67.6 ± 12.6* 68.4 ± 12.6
Body mass index 28.0 ± 7.4 26.9 ± 6.7* 26.7 ± 7.4* 26.9 ± 7.1*
Male sex 11605 (98.0) 647 (99.1) 627 (97.7) 884 (98.2)
White race 7623 (64.4) 407 (62.3) 402 (62.6) 593 (65.9)
Hispanic ethnicity 723 (6.1) 26 (4.0)* 37 (5.8) 51 (5.7)
Year
 2002–2005 4558 (38.5) 264 (40.4)* 273 (42.5)* 296 (32.9)*
 2006–2009 3824 (32.3) 242 (37.1)* 225 (35.1)* 368 (40.9)*
 2010–2013 3458 (29.2) 147 (22.5)* 144 (22.4)* 236 (26.2)*
 Intensive care at culture 1953 (16.5) 174 (26.7)* 146 (22.7)* 251 (27.9)*
Region of facility
 Midwest 2406 (20.3) 125 (19.1)* 128 (19.9)* 173 (19.2)*
 Northeast 1449 (12.2) 100 (15.3)* 125 (19.5)* 148 (16.4)*
 South 5233 (44.2) 300 (45.9)* 274 (42.7)* 395 (43.9)*
 West 2752 (23.2) 128 (19.6)* 115 (17.9)* 184 (20.4)*
Source of infection$
 Catheter 226 (1.9) 19 (2.9) 29 (4.5)* 11 (1.2)
 Endocarditis‡ 380 (3.2) 15 (2.3) 2 (0.3)* 65 (7.2)*
 Respiratory culture site 593 (5.0) 73 (11.2)* 81 (12.6)* 60 (6.7)*
 Skin and soft tissue culture site 1896 (16.0) 65 (9.9)* 43 (6.7)* 102 (11.3)*
 Urine 1392 (11.8) 49 (7.5)* 73 (11.4) 147 (16.3)*
 Other culture site 213 (1.8) 11 (1.7) 9 (1.4) 15 (1.7)
S. aureus pathogen
 MRSA infection 5336 (45.1) 359 (55.0)* 352 (54.8)* 411 (45.7)
 MSSA infection 6504 (54.9) 294 (45.0)* 290 (45.2)* 489 (54.3)
Median time to antibiotic treatment 
initiation from culture collection (days)
0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1)
Median length of antibiotic therapy 
(days)
9 (5–14) 8 (5–14) 11 (7–16)* 12 (8–18)*
Median time to culture collection from 
admission (days)
0 (0–3) 4 (0–14)* 6 (2–15)* 0 (0–1)*
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with continuation, despite a lower discharge rate 
(HR 0.74, 0.60–0.90), and a lower discharge rate 
was also observed for de novo PPI users (HR 0.75, 
95% CI 0.64–0.87; data not presented in tables).
Discussion
PPIs have been shown in various studies to inhibit 
neutrophil functions that are critical in bacterial 
clearance, including production of reactive oxida-
tive species, chemotaxis, and phagolysozome 
acidification.6,7 In addition, certain PPIs are 
reported to reduce expression of integrins CD11b 
and CD18 on the neutrophil surface and expres-
sion of adhesion molecules ICAM-1 and VCAM-1 
on endothelial cells, potentially compromising 
transcytosis of the immune cells to tissue foci of 










De novo  
(n = 900)
Surgery during the current admission 4288 (36.2) 251 (38.4) 260 (40.5)* 314 (34.9)
Comorbidity during current admission
 Charlson score 3.2 ± 2.5 3.7 ± 2.9* 3.6 ± 2.9* 2.8 ± 2.5*
 Elixhauser score 3.6 ± 1.9 3.9 ± 2.0* 3.8 ± 1.9 3.6 ± 1.9
 Sepsis 9814 (82.9) 516 (79.0)* 487 (75.9)* 773 (85.9)*
 Shock 498 (4.2) 45 (6.9)* 36 (5.6) 91 (10.1)*
  Coagulation and hemorrhagic 
disorders
56 (0.5) 3 (0.5) 10 (1.6)* 4 (0.4)
 Peptic ulcer disease 89 (0.7) 26 (4.0)* 37 (5.8)* 16 (1.8)*
  Peptic ulcer disease excluding 
bleeding
33 (0.3) 8 (1.2)* 10 (1.6)* 7 (0.8)*
 Gastrointestinal hemorrhage 65 (0.6) 21 (3.2)* 34 (5.3)* 7 (0.8)
Medical conditions prior to current admission§
 Charlson score 3.3 ± 2.9 3.5 ± 3.2 2.9 ± 3.2* 2.3 ± 2.7*
 Elixhauser score 3.9 ± 2.7 4.1 ± 2.7 3.3 ± 2.0* 2.8 ± 2.5*
 S. aureus infection 530 (4.5) 30 (4.6) 24 (3.7) 32 (3.6)
 Influenza vaccination 1516 (12.8) 92 (14.1) 72 (11.2) 85 (9.4)*
 Surgery 3574 (30.2) 193 (29.6) 152 (23.7)* 201 (22.3)*
 Hospitalization 6106 (51.6) 395 (60.5)* 318 (49.5) 328 (36.4)*
 Nursing home stay 908 (7.7) 64 (9.8)* 54 (8.4) 63 (7.0)
Data are mean ± standard deviation, number (%) of patients, or median (interquartile range).
*p < 0.05 for pairwise comparison between PPI exposure group and non-user group.
$Culture-confirmed source of infection ± 24 hours from culture collection unless indicated otherwise.
‡Source of infection identified from ICD-9-CM diagnosis codes ± 24 hours from culture collection.
§Present in the 1 year prior to the Staphylococcus aureus bacteremia hospitalization.
ICD-9-CM, International Classification of Diseases, 9th edition, clinical modification; MRSA, methicillin-resistant S. aureus; 
MSSA, methicillin-susceptible S. aureus; PPI, proton-pump inhibitor.
Table 1. (Continued)
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Table 2. Clinical outcomes in propensity-matched proton-pump inhibitor users and nonusers.
Outcomes Events, n/patients, n HR (95% CI)  
PPI users Nonusers  
30-day mortality
 Pretreated without continuation 153/632 129/632 1.24 (0.97–1.60)
 Pretreated with continuation 168/683 169/683 0.91 (0.72–1.14)
 De novo 178/1006 190/1006 0.87 (0.71–1.08)
14-day mortality
 Pretreated without continuation 100/632 92/632 1.16 (0.86–1.55)
 Pretreated with continuation 97/683 136/683 0.66 (0.50–0.87)
 De novo 100/1006 126/1006 0.77 (0.59–1.00)
Inpatient mortality
 Pretreated without continuation 127/632 110/632 1.26 (0.91–1.74)
 Pretreated with continuation 142/683 139/683 0.80 (0.59–1.08)
 De novo 166/1006 169/1006 0.78 (0.59–1.04)
Discharge
 Pretreated without continuation 505/632 522/632 1.04 (0.87–1.23)
 Pretreated with continuation 541/683 544/683 0.78 (0.65–0.92)
 De novo 840/1006 837/1006 0.85 (0.74–0.97)
ICU discharge
 Pretreated without continuation 123/167 121/165 1.75 (0.86–3.56)
 Pretreated with continuation 113/151 114/152 0.47 (0.21–1.05)
 De novo 204/262 201/272 0.75 (0.44–1.27)
30-day readmission
 Pretreated without continuation 137/505 132/522 1.11 (0.84–1.49)
 Pretreated with continuation 127/541 131/544 0.90 (0.67–1.20)
 De novo 181/840 208/837 0.86 (0.68–1.09)
30-day Clostridium difficile infection
 Pretreated without continuation 5/505 6/522 0.75 (0.17–3.35)
 Pretreated with continuation 12/541 7/544 1.40 (0.44–4.41)
 De novo 8/840 13/837 0.67 (0.27–1.63)
Propensity score matched within a 0.005 caliper range. The propensity score was derived from an  
unconditional logistic regression model and controlled for the variables listed in Appendix 1 in  
the Supplementary Material.
Bold text indicates statistical significance.
CI, confidence interval; HR, hazard ratio; ICU, intensive care unit.
0 1 2
HR
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previous clinical evidence suggesting poorer clini-
cal outcomes in patients treated with PPIs, 
including increased risk for C. difficile infections 
and mortality.2,3
Seeking to determine whether PPIs influence 
clinical outcomes in patients with S. aureus bac-
teremia, we found similar outcomes between PPI 
users with varying exposure patterns as compared 
with nonusers, in agreement with a recent meta-
analysis of 19 randomized trials conducted 
among critically ill patients.9 As the included 
randomized trials evaluated prophylactic PPI 
use, these studies most likely reflect a de novo 
exposure pattern, however the number of studies 
excluding patients with preadmission PPI use 
was not reported. Pneumonia, mortality, and 
ICU length of stay were similar among those ran-
domzied to PPIs versus histamine-2-receptor 
antagonists (H2RAs), with a relative risk of 1.12 
(95% CI 0.86–1.46) and 1.05 (95% CI 0.87–
1.27) for pneumonia and mortality, respectively, 
and a mean difference in ICU length of stay of 
−0.38 days (95% CI −1.49 to 0.74). None of the 
included 19 studies reported CDIs.
While multiple meta-analyses have found an asso-
ciation between PPI use and CDIs, heterogeneity 
among studies evaluated has been consistently 
high (I2 > 85%) reflecting variability in the asso-
ciated risk among studies, and significant limita-
tions of existing studies have been noted.10,11 A 
recent study evaluating the risk of CDI among 
intensive care unit patients suggests some patient 
populations may not have the same associated 
risk, consistent with our results.12 In this large 
multicenter study among 18,134 patients, PPI 
use did not lead to a significant increase in CDI 
[adjusted hazard ratio (aHR) 1.56; 95% CI 0.72–
3.35] among patients not receiving antibiotics 
and was protective in those receiving antibiotics 
(aHR 0.64; 95% CI 0.48–0.83). Further studies 
should seek to determine in which patient popu-
lations PPIs may be safely used without confer-
ring increased CDI risk.
Several limitations to our study should be noted. 
First, over-the-counter use of PPIs may not have 
been reported during clinical visits and hospitali-
zations. Second, we utilized diagnosis codes to 
operationally define certain conditions, such as 
CDI, which may result in misclassification. For 
example, presence of diagnosis codes may not 
always reflect active problems and may be used to 
reflect history of the condition, or even coloniza-
tion in the case of C. difficile. Third, residual con-
founding may be present due to unmeasured 
confounders, despite our efforts to control for 
many confounders using propensity-score meth-
ods. Fourth, our study was conducted among 
patients receiving care at VA hospitals, and 
included mostly older males.
Conclusion
Rates of negative clinical outcomes were similar 
among PPI users and nonusers in our large, 
national, real-world cohort study. As this is one 
observational study from a single-study popula-
tion, our results should be substantiated in other 
study populations. If rates of negative clinical out-
comes, such as mortality and CDI, are found to 
be similar between PPI users and nonusers with 
serious infections then the clinical benefits of PPI 
use under appropriate indications may outweigh 
the potential risk of certain other adverse events 
that have been attributed to PPI use.
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